Introduction. There are very few antiviral medicine which is allowed for use in children. The aim: to  evaluate the efficiency of Viferon in complex therapy of children with viral encephalitis (VE). The object. 75 patients with VE from 3 months to 3 years of old. The main group - 57 people, got a complex antiviral therapy of wide spectrum – recombinant interferon-a2 Viferon, which is allowed for use in children from birth. Viferon provides antiviral and immune modulatory effect and it suppresses viral replication. Children with proven diagnosis got suppositories Viferon. The comparison group contained 18 patients with VE, comparable on sex, age groups, cause of the disease and etiology, who got complex therapy (acyclovir, cytoflavin, methylprednisolone). Methods. Monitoring of neurological status, virology, radiology, immunology. Results. Etiology of VE: 68% all herpes viruses, 10,7%  enteroviruses, 2,6% virus of tick-born encephalitis and rubella virus. Acute cause VE was in 74,7% cases, lingering cause – in 12%, chronicle - 9,3%. In the main group were determined: the a significant reduction in the duration of commoninfectional syndrome, viremia, repeated exacerbations, a reduction in the frequency of residual neurologic deficit and cystic-gliosis-atrophic process in the central nervous system, significantly accelerated restoration of normal production interferon-α in blood. Side effects of Viferon were not revealed. Conclusion. The use of suppositories Viferon  in complex therapy children with VE under 3 old  is safe, effective and helps to improve the disease outcomes.